T1	Participants 523 735	prospective, double-blind study, 31 patients receiving pelvic radiotherapy were randomized to receive two sulfasalazine 500-mg tablets twice daily or placebo, administered orally from the first day of irradiation
T2	Participants 737 768	Patients were evaluated weekly,
T3	Participants 974 1094	week 5, the subjects were graded endoscopically, and biopsies taken from the rectum were classified histopathologically.
T4	Participants 1103 1178	Groups did not differ in age, gender, tumor site, or irradiation procedure.
T5	Participants 1581 1724	Long-term follow-up with the subjects will help to determine the net effect of sulfasalazine on the radiation-induced gastrointestinal injuries
